Industry prepared to pay for 'alarmingly expensive' Phase I deals

摘要

The cost of licensing in Phase I compounds is escalating out of proportion as demand outstrips supply in the wake of pharmaceutical companies' attempts to fill pipelines, industry executives told last week's Licensing Executives Society conference in New York."The trend is alarming. It is difficult to understand how the valuations will work out " said Tony Rosenberg,head of global business development and licensing at Novartis.